These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses. Qu Q; Zhai Z; Xu J; Li S; Chen C; Lu B Front Immunol; 2020; 11():634. PubMed ID: 32351508 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for advanced melanoma: Current knowledge and future directions. Nakamura K; Okuyama R J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423 [TBL] [Abstract][Full Text] [Related]
14. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817 [TBL] [Abstract][Full Text] [Related]
15. Harnessing the immune system for the treatment of melanoma: current status and future prospects. Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898 [TBL] [Abstract][Full Text] [Related]
16. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of patients with metastatic melanoma. Yu Z; Si L Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673 [TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Eggermont AM; Maio M; Robert C Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]